We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CEL-SCI has been issued a U.S. patent, titled "A Method of Pre-Sensitizing
Cancer Prior to Treatment With Radiation and/or Chemotherapy and a Novel Cytokine
Mixture," covering its cancer drug, Multikine.
The U.S. Patent and Trademark Office has issued a patent protecting the use
of GlycoGenesys' drug candidate GCS-100 and other modified pectins to control
angiogenesis (the process by which new blood vessels are formed) and to treat
angiogenesis-dependent diseases.
Hybridon has entered into research collaboration and license agreements with
Novartis for the discovery, optimization, development and commercialization
of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy
based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology
platform.
In one of the largest adult vaccine clinical trials ever, researchers have found
that an experimental vaccine against shingles (zoster vaccine) prevented about
half of cases of shingles -- a painful nerve and skin infection -- and
dramatically reduced its severity and complications in vaccinated persons who
got the disease, according to the National Institute of Allergy and Infectious
Diseases (NIAID).
Peregrine Pharmaceuticals has published a research article, titled "Safety
and Feasibility of Convection-Enhanced Delivery of Cotara for the Treatment
of Malignant Glioma: Initial Experience in 51 Patients," in the journal
Neurosurgery that validates the use of convection-enhanced delivery (CED)
for administering Cotara to patients with brain cancer.
Favrille has enrolled 220 eligible patients into its Phase III registration
clinical trial testing its lead product candidate, FavId, following Rituxan
in patients with follicular non-Hodgkin's lymphoma.
Insmed has announced updated results for the company's pivotal Phase III clinical
trial evaluating SomatoKine (mecasermin rinfabate), a once daily insulin-like
growth factor I (IGF-I) replacement therapy delivered as a proprietary complex
of rhIGF-I/rhIGFBP-3, in children with short stature due to growth hormone (GH)
insensitivity syndrome (GHIS).
Neurocrine Biosciences has completed submission of a new drug application (NDA)
to the FDA for indiplon tablets for the treatment of insomnia in both adult
and elderly patients.